Illumina is expanding beyond sequencing reagents into data offerings for pharmaceutical partners, launching a BioInsight unit to shoulder sequencing‑intensive projects and retain ownership of resulting datasets. CEO Jacob Thaysen said Illumina will develop and monetize complex datasets — including Perturb‑seq scale experiments — and expects to offer limited exclusivity to partners before broader commercialization. The strategy reflects a wider industry shift: genomics providers and synthetic biology firms are packaging experimental data and analytics as products to feed AI models and drug discovery pipelines. Illumina said the approach could change how pharma buys genomics work, with the company combining wet lab execution and computational services to generate high‑value training datasets. Competitors such as Ginkgo and Twist are also moving into data productization, signaling a market pivot toward integrated data generation, curation and analytics that supports AI‑driven discovery and translational research.